Huperzine A: what it is and how it works

Huperzine A (HupA) is a powerful and promising neuroprotectant. It is an alkaloid with a number of nootropic properties, found in the Chinese club moss Huperzia serrata. It has been used for centuries in traditional Chinese medicine to treat dementia. The effects of this alkaloid are related to its ability to suppress the cholinergic enzyme acetylcholinesterase (AChE), acting as an acetylcholinesterase inhibitor (AChEI), thereby exerting a beneficial effect on the metabolism of the neurotransmitter acetylcholine.

Acetylcholine is one of the most reliable, powerful, and important assistants for both the central and peripheral nervous systems – where it is responsible for muscle activation and improves the contractility of both skeletal and heart muscles.

Furthermore, Huperzine A is extremely important for memory, focus, attention, cognitive abilities, aging, and brain longevity.

It has been established that the intake of this alkaloid compound increases acetylcholine levels and protects neurons from oxidative damage.

The biological functions of HupA have been studied both in vitro and in vivo. Its role in neuroprotection makes it a good therapeutic candidate for the prevention of neurodegenerative diseases, especially Alzheimer's disease.

The neuroprotective effects of HupA focus on its interactions with various molecular signaling pathways, such as Wnt signaling, pre- and postsynaptic area mechanisms (synaptotagmin, neuroligins), amyloid precursor protein (APP), amyloid-β peptide (Aβ) processing, and mitochondrial protection.

Huperzine A protects neurons from oxidative damage and mitochondrial dysfunction caused by beta-amyloids. The beta-amyloid protein is a primary cause of brain neuron death and the development of Alzheimer's disease. Lowering the concentration of this protein is now seen as an optimal tactic for the prevention of neurodegenerative diseases.

HupA is an unsaturated sesquiterpene alkaloid compound that effectively crosses the blood-brain barrier. It shows excellent bioavailability and has a long bioactive lifespan, acting as a mixed-competitive, reversible, and selective AChE inhibitor with a half-life of 5 hours in the bloodstream. It reaches peak concentration at 60 minutes in humans, and its t½ is calculated at approximately 4–5 hours.

In numerous clinical studies, HupA is cited as a proven agent for improving cognitive function and memory in both elderly and younger individuals. It stimulates memory and maintains cognitive reserve because it also stimulates the secretion of NGF – Nerve Growth Factor, which plays a key role in the proper functioning of the nervous system.

Current scientific research shows that Huperzine A can increase sleep duration, having a particularly pronounced effect /by 20-30%/ on the REM phase, the rapid eye movement phase where we dream. In this way, again linked to the regulation of acetylcholine levels, Huperzine A is of great importance for brain development, memory, mood, and peak cognitive potential. It supports the retention and fixation of memory traces.

Studies show that stress, physical inactivity, and a hectic workday lead to the accumulation in the brain of a potentially toxic agent called glutamate.

Glutamate, besides being a marker for fatigue and overwork, is also a type of metabolite, and the brain clears this toxic waste product primarily during sleep.

In large amounts, however, glutamate alters the functioning of a part of the brain – namely the lateral prefrontal cortex (LPFC), which is involved in decision-making and planning processes. In the last decade, it has been proven that glutamate damages the retina and is part of the pathophysiological process in the onset of Parkinson's and Alzheimer's disease.

In this line of thought, Huperzine A becomes particularly valuable for another reason as well. Clinical studies show that HupA is a non-competitive NMDA antagonist that exerts a neuroprotective effect against glutamate-induced neuronal damage and cell death.